WASHINGTON, Sept. 20, 2016 -- Media accreditation now is open, with new launch dates, for the next NASA-contracted cargo resupply flight launching from Virginia to the International Space Station.
Orbital ATK is targeting no earlier than Oct. 9-13 for the launch of its Cygnus spacecraft on an Antares rocket from the Mid-Atlantic Regional Spaceport's Pad-0A at NASA's Wallops Flight Facility in Wallops Island, Virginia. A more specific date will be identified after completion of final operational milestones and technical reviews. Launch times range from 10:47 p.m. EDT Sunday, Oct. 9 to 9:13 p.m. Thursday, Oct. 13.
International media without U.S. citizenship must have previously applied for credentials to cover the prelaunch and launch activities at Wallops. The application deadline is Friday, Sept. 30 for media who are U.S. citizens. Media should send their accreditation request to Keith Koehler at [email protected]. For questions about accreditation or additional information, contact Koehler by email or at 757-824-1579.
This will be the sixth planned cargo resupply mission by Orbital ATK under NASA's Commercial Resupply Services contract with the company and the fourth launch from Virginia. Cargo resupply by U.S. companies enables a national capability to deliver critical science research to the space station, significantly increasing NASA's ability to conduct new science investigations aboard the world's only microgravity laboratory.
Get more information about Orbital ATK, its Antares rocket and the Cygnus cargo spacecraft at:


NASA's Artemis II Mission: First Crewed Lunar Journey Since Apollo
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug
Neuralink Expands Brain Implant Trials with 12 Global Patients
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 



